leadXpro has just elucidated the world’s first structure of a proton-sensing GPCR target
To date, no structural information has been reported for the entire H+ activated GPCR family.
news
Latest developments, partnerships and scientific breakthroughs
Colocalized targeting of TGF-beta and PD-L1 by bintrafusp alfa elicits distinct antitumor responses
In collaboration with Merck/Serono, leadXpro confirmed the colocalization aspect of the mode of action of bintrafusp alfa using Cryo-Electron Microscopy
leadXpro joins the MabDesign Network
leadXpro AG is a sponsor of the MabDesign Network, which aims at structuration of the immunotherapeutics research sector.
CEO Michael Hennig presents at Drug Discovery Chemistry 2022
Listen to Michael Hennig’s talk at DDC 2022 about the impact of CGI and other biophysical methods on drug discovery for membrane proteins
Attend leadXpro’s lecture on Cryo-EM at PSDI 2021
The PSDI conference 2021 will take place online. leadXpro scientist Mathieu Botte will present on Cryo-EM applications.
M&M 2021 virtual meeting
At the M&M meeting, leadXpro CEO Michael Hennig will present «Advances in Cryo-EM structure-based methods in membrane protein drug discovery», highlighting recent work on TRPV4, LPTDE and a potassium channel.
CryoEM Structure of Lipopolysaccharide Transporter LptDE Opens the Door to Antibiotics Design
Together with the Basel Biozentrum and the Institute of Medical Microbiology in Zurich, leadXpro solved the structure of the bacterial transporter LptDE to provide structural basis for the design of novel antibiotics.
Meet leadXpro CEO Michael Hennig at the Symeres Webinar
leadXpro CEO Michael Hennig showcases examples of successful structure based drug discovery for challenging membrane targets
Join us at the Creoptix waveRAPID launch event
leadXpro supports Creoptix at the launch event for the new waveRAPID kinetics analyzer
leadXpro celebrates its 5th anniversary
On December 2, 2020, leadXpro proudly celebrates its fifth anniversary and looks back on many successful projects with challenging membrane targets.